A biotech client developing a pre-clinical blood cancer treatment needed to understand its market opportunity. Without a clear picture of the landscape or the evidence requirements for market access and investment, they risked missing critical milestones. Their goal was to build a compelling early value proposition that would resonate across stakeholders, from investors to potential partners.
Our team launched a rapid, high-impact assessment combining expert consulting and data science. We started by mapping the disease and treatment landscape through a systematic literature review and layered this with competitor analysis focused on both pipeline and mechanism of action. To validate opportunity size, we conducted an epidemiological analysis enriched with forecast modelling to estimate the addressable patient population and unmet need. These insights were built into an interactive intelligence board, giving the client a dynamic view of the data along with strategic guidance on how best to use it.
Following the initial engagement, we continued to support the client through software enhancements. We updated the intelligence board to include live epidemiological models and new data layers. This helped them further refine their understanding of the opportunity and adapt their messaging as new developments emerged.
